About Ovensa

Ovensa is a pre-clinical stage company that capitalizes on its proprietary TRIOZAN™ Nanomedicine Delivery Platform to solve barrier crossing, intracellular uptake and therapeutic resistance challenges in complex diseases. The company focuses on oncology/immuno-oncology, neurodegenerative diseases and antimicrobial resistance.


Ovensa is seeking for strategic partnerships with pharmaceutical, generic and biotech companies interested to reformulate or repurpose proprietary and off-patent molecules (biologic and small molecule) with its TRIOZAN™ Nanomedicine Delivery Platform applicable in a fast track regulatory approval pathway.